Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Callisto Pharmaceuticals Appoints Vice President, Regulatory Affairs

By Pharmaceutical Processing | January 19, 2005

NEW YORK (January 18, 2005) — Callisto Pharmaceuticals, Inc., a biopharmaceutical company primarily focused on the development of drugs to treat cancer and osteolytic bone disease, has announced the appointment of Paula Craft to the newly-created position of Vice President, Regulatory Affairs.

Craft brings to Callisto more than 18 years of regulatory, quality and compliance experience in biologics and pharmaceuticals.

“Callisto has two drugs that will be in clinical trials in 2005,” said Dr. Donald Picker, executive vice president, research and development. “To drive these programs, it is imperative we have an executive of Paula’s caliber to manage regulatory affairs and product direction throughout the entire product lifecycle, from strategy, government regulation, quality assurance and testing, through distribution partnerships and product launch. We look forward to having Paula join our team.”

Craft most recently held the position of president, regulatory compliance, quality systems and strategic planning for Biopharmaceutical Consulting. In this role, she led the company’s efforts in drug safety, internal audits and testing, supply chain management, software program selection, product testing and compliance, budget planning, and quality control.

Prior to her role at Biopharmaceutical Consulting, she held vice president and senior director level product support, quality assurance and compliance positions with Alexion Pharmaceuticals, Johnson & Johnson, and American Home Products. She received her bachelor’s degree from the University of Rhode Island and continued her graduate studies at Eastern Connecticut State University and Rutgers (University of Medicine and Dentistry of New Jersey).

Related Articles Read More >

These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
Thermo Fisher Scientific
Thermo Fisher to invest $2B on U.S. manufacturing
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE